340B program reaches $100 billion in sales, while patients are left behind

The 340B Drug Pricing Program has grownyet again, exceeding$100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost. Recentdata from IQVIA shows 340B grew 12.2% year-over-year in 2022, continuing a trend in which 340B sales have almost doubled since 2018, outpacing growth of the total U.S. drug market.
Source: The Catalyst - Category: Pharmaceuticals Tags: 340B Source Type: news